Studies in Paget's disease and their relevance to oncology

https://doi.org/10.1016/S0093-7754(01)90227-1Get rights and content

Abstract

Paget's disease and bone metastases in cancer patients share many common properties. Both are characterized by a localized increase in osteoclast (OCL) formation leading to bone resorption. In both Paget's disease and bone metastases the increased OCL formation and the increased osteoclastogenic nature of the bone microenvironment are mediated by common factors, namely interleukin (IL)-6 and RANK ligand (RANKL). Available data suggest that in the case of Paget's disease there is increased RANKL and IL-6 production, and IL-6 enhances the responsivity of the OCL precursors to RANKL, contributing to the elevated numbers of OCLs. In patients with multiple myeloma, 95% to 100% of whom develop bone lesions, both IL-6 and RANKL levels are increased. Bisphosphonates bind locally to the surfaces of the bone undergoing osteoclastic resorption to inhibit this process. Paget's disease has in the past and will continue in the future to provide a model to test the efficacy of bisphosphonates in inhibiting bone resorption. Paget's disease provides an ideal model in which to investigate the efficacy of the new third-generation bisphosphonates in the treatment of bone metastases as well as nonmalignant bone disease.

References (31)

  • SD Neale et al.

    Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D (3) and RANKL

    Bone

    (2000)
  • TJ Chambers

    Regulation of the differentiation and function of osteoclasts

    J Pathol

    (2000)
  • C Menaa et al.

    Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of the bone

    J Clin Invest

    (2000)
  • RJ Thomas et al.

    Breast cancer cells interact with osteoblasts to support osteoclast formation

    Endocrinology

    (1999)
  • FR Singer et al.

    Bisphosphonates in the treatment of disorders of mineral metabolism

    Adv Endocrinol Metab

    (1995)
  • Cited by (23)

    • RANKL-independent modulation of osteoclastogenesis

      2019, Journal of Oral Biosciences
      Citation Excerpt :

      These results suggest that IL-1RI expression is the most critical prerequisite for osteoclasts or precursors to respond to IL-1. IL-6 is a pro-inflammatory cytokine that has been implicated in diseases associated with bone loss, such as postmenopausal osteoporosis, rheumatoid arthritis, and Paget's disease [46,47]. IL-6 can indirectly promote osteoclast formation and activation by inducing RANKL production in osteoblastic/stromal cells [48,49].

    • Prevention and management of bone metastases in lung cancer a review

      2009, Journal of Thoracic Oncology
      Citation Excerpt :

      Bisphosphonates are a group of compounds that are stable analogues of naturally occurring inorganic pyrophosphate. When bound to hydroxyapatite, they are specific inhibitors of osteoclast activity and this subsequently leads to inhibition of bone resorption.40–42 The most commonly investigated bisphosphonates in cancer are the first-generation compound clodronate (Bonefos; Schering AG, Berlin, Germany), second-generation pamidronate (Aredia; Novartis Pharmaceuticals Corporation, East Hanover, NJ), third-generation zoledronic acid (Zometa; Novartis Pharma Stein AG, Stein, Switzerland), and third-generation ibandronate (Boniva; Roche Laboratories Inc., Nutley, NJ).

    • P

      2007, Geriatric Clinical Advisor
    • P

      2006, Geriatric Clinical Advisor: Instant Diagnosis and Treatment, Book, Website
    View all citing articles on Scopus
    1

    Dr Roodman has served on the speakers' bureau for Novartis.

    View full text